No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Adherium Limited specializes in developing, manufacturing, and providing advanced digital health solutions. The company's core mission is to enhance medication adherence for individuals managing chronic conditions in key international markets, spanning New Zealand, Australia, Europe, North America, and Asia. A central offering is Hailie, a comprehensive system engineered to optimize medication use for patients suffering from chronic respiratory illnesses like asthma and chronic obstructive pulmonary disease (COPD). This innovative solution integrates Bluetooth-enabled Hailie sensors, which discreetly attach to patients' inhalers to deliver immediate feedback. The Hailie ecosystem is further supported by an intuitive mobile application and a dedicated online portal. Established in 2001, Adherium Limited is headquartered in Auckland, New Zealand.
www.adherium.comNo one on the platform currently holds ADR.AX.
No tracked institution reports a position in ADR.AX as of their last filing.
No one on the platform has traded ADR.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 157.0% | 39.3% | ||||
| Profit Margin % | -674.2% | -1129.7% | -1104.1% | |||
| Free Cash Flow Margin % | -708.1% | -1071.7% | -964.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $7M | +363.4% | $-7.90 | $-7.90–$-7.90 | — | 1 |
| 2028 | $31M | +325.3% | $5.26 | $5.26–$5.26 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ADR.AXAdherium Limited | $0.09 | +0.00% | $2M | — |
| BGT.AXBio-Gene Technology Limited | $0.02 | +0.00% | $5M | — |
| CAN.AXCann Group Limited | $0.01 | +0.00% | $4M | — |
| HIQ.AXHITIQ Limited | $0.00 | -11.11% | $4M | — |
| ICR.AXIntelicare Holdings Limited | $0.02 | +9.52% | $11M | — |
| IRX.AXInhaleRx Limited | $0.03 | +0.00% | $7M | — |
| IVX.AXInvion Limited | $0.04 | +0.00% | $5M | — |
Source: Financial Modeling Prep · peers by sector/industry